NEWS
All News
FDA Briefs
Oncology Icons
Special Reports
The Targeted Pulse
Voices from the Field
CONFERENCES
Conference Coverage
Conference Listing
Data Dialogue with the Oncology Brothers
MEDIA
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Pivotal Practice Views with the Oncology Brothers
Podcasts
Precision Medicine
Speaking Out
PUBLICATIONS
All Publications
Evolving Paradigms
Peers & Perspectives in Oncology
Targeted Therapies in Oncology
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CE
Clinical Trials
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
Choose Specialty
BRAIN CANCER
BREAST CANCER
BREAST CANCER
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENOMIC TESTING
GENOMIC TESTING
GI CANCERS
GI CANCERS
GI CANCERS
GI CANCERS
GI CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGY
HEMATOLOGY
IMMUNOTHERAPY
IMMUNOTHERAPY
LEUKEMIAS
LEUKEMIAS
LEUKEMIAS
LEUKEMIAS
LUNG CANCER
LUNG CANCER
LUNG CANCER
LUNG CANCER
LUNG CANCER
LYMPHOMAS
LYMPHOMAS
LYMPHOMAS
LYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERS
SKIN CANCERS
THYROID CANCERS
Spotlight -
Biomarker-Driven Lung Cancer
GIST
HER2 Breast Cancer
Chronic Lymphocytic Leukemia
Small Cell Lung Cancer
Renal Cell Carcinoma
Choose Specialty
BRAIN CANCER
BREAST CANCER
BREAST CANCER
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENITOURINARY CANCERS
GENOMIC TESTING
GENOMIC TESTING
GI CANCERS
GI CANCERS
GI CANCERS
GI CANCERS
GI CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
GYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGY
HEMATOLOGY
IMMUNOTHERAPY
IMMUNOTHERAPY
LEUKEMIAS
LEUKEMIAS
LEUKEMIAS
LEUKEMIAS
LUNG CANCER
LUNG CANCER
LUNG CANCER
LUNG CANCER
LUNG CANCER
LYMPHOMAS
LYMPHOMAS
LYMPHOMAS
LYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERS
SKIN CANCERS
THYROID CANCERS
Spotlight
NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE
Advertisement
FDA Approval of Axatilimab (Phase 2 AGAVE-201)
: Episode 3
Results of the AGAVE-201 Study
September 19, 2024
By
Rahul Gosain, MD
Rohit Gosain, MD
Shernan Holtan, MD
View All
Opinion
Video
Panelists discuss what the AGAVE-201 study displayed.
EP: 1.
Overview of Graft-Versus-Host Disease
EP: 2.
Overview of Chronic Graft-Versus-Host Disease, and AGAVE-201 Study Design
Now Viewing
EP: 3.
Results of the AGAVE-201 Study
EP: 4.
Sequencing Axatilimab and Safety
Recent Videos
Related Content
Related Content
